Comerica Bank Increases Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Share on StockTwits

Comerica Bank lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 36.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,187 shares of the medical device company’s stock after acquiring an additional 6,982 shares during the period. Comerica Bank’s holdings in DexCom were worth $3,849,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. California Public Employees Retirement System raised its stake in shares of DexCom by 29.5% during the 3rd quarter. California Public Employees Retirement System now owns 181,070 shares of the medical device company’s stock worth $27,023,000 after buying an additional 41,271 shares during the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its stake in shares of DexCom by 7.1% during the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 28,503 shares of the medical device company’s stock worth $4,254,000 after buying an additional 1,889 shares during the last quarter. Handelsbanken Fonder AB acquired a new position in shares of DexCom during the 3rd quarter worth $2,239,000. Commonwealth Equity Services LLC raised its stake in shares of DexCom by 3.8% during the 3rd quarter. Commonwealth Equity Services LLC now owns 5,855 shares of the medical device company’s stock worth $873,000 after buying an additional 214 shares during the last quarter. Finally, BB&T Securities LLC raised its stake in shares of DexCom by 10.4% during the 3rd quarter. BB&T Securities LLC now owns 7,200 shares of the medical device company’s stock worth $1,075,000 after buying an additional 681 shares during the last quarter. Institutional investors and hedge funds own 96.19% of the company’s stock.

In other news, CEO Kevin R. Sayer sold 10,000 shares of the company’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $156.12, for a total transaction of $1,561,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Heather S. Ace sold 7,243 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $174.80, for a total value of $1,266,076.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 105,222 shares of company stock valued at $16,407,406. 1.80% of the stock is currently owned by company insiders.

Several research firms have recently issued reports on DXCM. UBS Group lifted their price target on DexCom from $160.00 to $185.00 and gave the stock a “neutral” rating in a research note on Thursday. Zacks Investment Research raised DexCom from a “hold” rating to a “buy” rating and set a $154.00 price target for the company in a research note on Friday, October 25th. Piper Jaffray Companies lifted their price target on DexCom from $182.00 to $200.00 and gave the stock an “overweight” rating in a research note on Thursday. Guggenheim upgraded DexCom from a “neutral” rating to a “buy” rating in a research report on Thursday. Finally, Oppenheimer lifted their price objective on DexCom from $180.00 to $205.00 in a research report on Thursday. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. DexCom currently has an average rating of “Buy” and a consensus target price of $190.67.

DexCom stock opened at $198.08 on Friday. The company has a debt-to-equity ratio of 1.56, a quick ratio of 5.64 and a current ratio of 6.05. The firm has a market capitalization of $14.00 billion, a PE ratio of 660.27 and a beta of 0.64. The stock’s 50 day moving average price is $155.57 and its 200 day moving average price is $146.29. DexCom, Inc. has a one year low of $105.05 and a one year high of $200.80.

DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, November 6th. The medical device company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.20 by $0.45. DexCom had a positive return on equity of 10.41% and a negative net margin of 13.96%. The business had revenue of $396.30 million during the quarter, compared to the consensus estimate of $348.99 million. During the same period in the prior year, the business posted $0.17 earnings per share. DexCom’s revenue was up 48.6% compared to the same quarter last year. On average, analysts forecast that DexCom, Inc. will post 0.94 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Article: How do CD ladders protect against rising interest rates?

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.